Nicorandil in the Treatment of Angina Pectoris

Introduction to Nicorandil Therapy

• The European Society of Cardiology recommends beta-blockers as the preferred first-line treatment for angina due to their proven benefits in reducing heart failure hospitalization and mortality 1, 2
• Nicorandil may be considered as a second-line antianginal agent in patients with persistent angina despite beta-blocker therapy or in those unable to tolerate beta-blockers, but its safety in heart failure remains uncertain 1, 2, 3

Place in Therapy for Angina Pectoris

• The European Society of Cardiology suggests alternative first-line options when beta-blockers cannot be tolerated, including ivabradine (Class IIa, Level A), oral or transcutaneous nitrates (Class IIa, Level A), amlodipine (Class IIa, Level A), and nicorandil (Class IIb, Level C) 1, 2
• Nicorandil may be considered when angina persists despite treatment with a beta-blocker (or alternative first-line agent) 1, 2

Treatment Algorithm and Guideline Recommendations

• The European Society of Cardiology recommends a treatment algorithm for angina, starting with beta-blockers as first-line therapy, followed by alternative agents such as ivabradine, nitrates, amlodipine, or nicorandil if symptoms persist or beta-blockers are contraindicated 1, 2, 3, 4
• In the 2024 ESC guidelines for chronic coronary syndromes, nicorandil has been downgraded to a Class IIb recommendation (may be considered) as add-on therapy for inadequate symptom control 4

Important Contraindications and Precautions

• The European Society of Cardiology advises against combining nicorandil with nitrates due to lack of additional efficacy 1, 2, 3
• Combination of nicorandil with ivabradine or ranolazine is not recommended due to unknown safety 1, 2
• Use in patients with heart failure should be approached with caution as safety remains uncertain 1, 2

Nicorandil for Angina Treatment

Clinical Use and Efficacy

• The European Society of Cardiology recommends nicorandil as an alternative when beta-blockers cannot be tolerated, with a Class IIb, Level C recommendation, and it is typically administered at a usual dose of 20 mg twice daily for the prevention of angina 5
• Nicorandil may be used as monotherapy or in combination with other antianginal drugs when symptoms persist despite first-line treatment, according to the European Heart Journal 6
• The IONA outcome study showed that nicorandil significantly reduced the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction, or unplanned hospitalization for chest pain, with benefits primarily driven by reduction in unplanned hospitalization for unstable angina rather than mortality benefits 7

Safety and Precautions

• The main adverse effects of nicorandil include headache, reflux, tachycardia, facial flushing, and hypotension, and rare but serious skin, mucosal, and eye ulceration have been reported 7
• The concomitant use of nicorandil with aspirin might increase the risk of gastrointestinal ulcers, perforations, and hemorrhage 7

Potential Cardioprotective Effects

• Nicorandil is thought to have cardioprotective properties beyond its antianginal effects, and may protect the myocardium during ischemic events through its potassium channel activation mechanism 5
• A propensity-matched cohort of patients with chronic stable angina showed beneficial effects when followed for 7 years 7

Intravenous Nicorandil in Acute Coronary Syndromes and Related Cardiovascular Conditions

Indications & Dosing

• ESC (European Society of Cardiology) recommends intravenous nicorandil as an alternative to nitrates for patients with unstable angina when nitrate tolerance develops; this is a Class IIb, Level C recommendation. 8
• For acute coronary syndromes, the suggested IV bolus dose is 2–14 mg, followed by a continuous infusion that is titrated to the individual’s clinical response (e.g., relief of angina or hemodynamic targets). 8

Contra‑indications & Safety

• Co‑administration of nicorandil with phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) is contraindicated because of a high risk of severe hypotension; this is a Class I, Level C recommendation. 9
• Use of nicorandil in cardiogenic shock or severe hypotension is also contraindicated for the same reason. 9

Clinical Outcomes

• The IONA randomized trial (5,126 patients with stable angina) demonstrated that oral nicorandil reduced the composite endpoint of cardiovascular death, non‑fatal myocardial infarction, and unplanned hospitalization from 15.5 % to 13.1 % (hazard ratio 0.83; 95 % CI 0.72‑0.97; p = 0.014). This provides Level A evidence of benefit on morbidity. 10
• In the same IONA cohort, nicorandil did not produce a statistically significant reduction in coronary heart disease mortality or non‑fatal myocardial infarction (5.2 % → 4.2 %; HR 0.79; 95 % CI 0.61‑1.02; p = 0.068). 10

Treatment Algorithms for Microvascular and Vasospastic Angina

• Coronary microvascular disease: ESC 2023 guidance places nicorandil 5 mg twice daily as a third‑line option after beta‑blocker and calcium‑channel blocker therapy have failed. 11
• Vasospastic (Prinzmetal) angina: ESC 2023 recommends nicorandil 5 mg twice daily as a third‑line therapy after failure of a calcium‑channel blocker and a long‑acting nitrate. 11

Monitoring & Clinical Management

• During IV infusion, continuous blood pressure and heart‑rate monitoring is advised, with dose titration until anginal symptoms are relieved or adverse effects (e.g., hypotension, headache) emerge. This monitoring strategy is endorsed by the ESC. [8][10]
• If signs of hypotension such as dizziness or syncope appear—particularly when nicorandil is combined with a PDE‑5 inhibitor—prompt evaluation and drug discontinuation are recommended. 9

Comparative Therapies & Nitrate Tolerance

• IV nitroglycerin is typically administered at 5–200 µg/min and titrated to effect; tolerance usually develops after 7–8 hours of continuous infusion. (Circulation) 9
• Nicorandil can be used to circumvent nitrate tolerance, as suggested by ESC experience in acute coronary syndromes. [8][10]